With periodontal disease affecting more than 40% of American adults—and growing evidence linking oral bacteria to cardiovascular disease, diabetes, and pregnancy complications—dental practices are seeking faster, more precise diagnostic tools. ImpetusDX aims to meet that need with its new IDX Oral Health Microbial Testing panel, a rapid, DNA-based saliva test that detects high-risk periodontal pathogens in as little as 24 hours and can be seamlessly integrated into routine hygiene visits.
“Our panel is versatile and fits into existing hygiene, periodontal maintenance, or surgical planning workflows,” said Michelle Moore, CEO of Physicians Choice Labs, which powers the ImpetusDX platform. “Samples can be collected chairside during routine cleanings or when infection is suspected. The process is noninvasive, takes only minutes, and doesn’t disrupt the schedule.”
The test uses PCR technology to identify the specific bacteria driving infection, including emerging pathogens not covered by competitor panels. Clinicians receive a color-coded, semi-quantitativ
e report within 24 to 48 hours, enabling faster, more targeted diagnosis, treatment planning, and monitoring. With overnight shipping, Monday samples are reported by Tuesday, among the fastest turnarounds in the market.
Key Features Of The Impetusdx Panel Include
DNA-based detection of high-risk periodontal pathogens, including emerging organisms such as Selenomonas noxia, Filifactor alocis, Pseudomonas aeruginosa, and Streptococcus mutans, providing a four-pathogen advantage over many competing tests.
Seamless integration into daily workflows, from hygiene visits and periodontal maintenance to surgical planning and preventive evaluations.
Rapid, reliable results with overnight shipping and 24–48-hour reporting.
CAP-accredited, CLIA-certified laboratory processing and participation in the American Dental Association.
A six-step process from chairside collection to data-driven treatment pathways and retesting.
A list price of $189, with tiered discounts for higher-volume practices and modest insurance-eligible collection fees.
“Our panel delivers results in under 48 hours, offers a broader oral-systemic perspective, and provides hands-on clinical support for integration into routine care,” Moore said. “We also offer CE credits, educational forums, hygienist incentives, and pilot programs to build confidence and streamline adoption.”
Clinicians using the test report clearer treatment pathways, stronger patient acceptance, and a better understanding of the microbial drivers of periodontal disease. Objective PCR data helps differentiate inflammation from active bacterial infection and illustrates the oral-systemic connection for patients. Many practices also report financial benefits, including increased production and higher annual net revenue within the first year of adoption.
Related topic：
